Vast resources are expended during the development of new cancer therapeutics, and selection of optimal in vivo models should improve this process. Genetically engineered mouse models (GEMM) of cancer have progressively improved in technical sophistication and, accurately recapitulating the human cognate condition, have had a measureable impact on our knowledge of tumourigenesis. However, the application of GEMMs to facilitate the development of innovative therapeutic and diagnostic approaches has lagged behind. GEMMs that recapitulate human cancer offer an additional opportunity to accelerate drug development, and should complement the role of the widely used engraftment tumour models.

中文翻译：

---

预测体内动物模型并转化为临床试验。


新的癌症疗法的开发过程中消耗了大量的资源，而最佳体内模型的选择应该可以改善这一过程。癌症基因工程小鼠模型（GEMM）在技术复杂性方面不断提高，并且准确地再现了人类的同源状况，对我们对肿瘤发生的了解产生了可衡量的影响。然而，GEMM 在促进创新治疗和诊断方法开发方面的应用却滞后了。重现人类癌症的 GEMM 为加速药物开发提供了额外的机会，并且应该补充广泛使用的移植肿瘤模型的作用。